TABLE 2

Percentage Increases in SUV_mean, SUV_max, and SUR

				SUV_mean			SUV_max			SUR
Tracer	Study	ROIs	Motion (mm)^*	CTAC	NAC	AIM	CTAC	NAC	AIM	CTAC	NAC	AIM
¹⁸F-FDG	1	17	5.3 (2.0–8.3)	16.7 ± 19.5	18.2 ± 19.2	21.1 ± 18.4	13.9 ± 14.4	15.6 ± 16.0	15.6 ± 10.0	33.2 ± 22.3	35.0 ± 21.9	40.5 ± 21.3
	2	106	5.4 (1.7–9.4)	24.6 ± 26.6	22.4 ± 23.5	28.0 ± 28.7	19.7 ± 22.5	21.2 ± 26.1	22.6 ± 24.2	26.5 ± 27.0	21.1 ± 23.3	27.9 ± 26.8
	3	1	6.9	6.9	4.9	20.2	−0.4	0.1	20.5	13.2	7.8	26.9
	4	25	8.4 (2.5–16.2)	38.5 ± 48.8	30.8 ± 48.8	42.2 ± 50.3	26.6 ± 50.0	20.9 ± 50.6	29.2 ± 57.0	37.3 ± 48.4	29.5 ± 48.3	43.1 ± 50.6
	5	28	8.3 (3.8–25.2)	13 ± 19.4	16.3 ± 21.2	19.3 ± 20.6	10.6 ± 23.8	14.5 ± 28.9	11.2 ± 21.1	12.0 ± 19.2	15.2 ± 21.0	19.3 ± 20.6
	6	3	3.0 (1.6–4.2)	7.0 ± 3.8	2.8 ± 6.8	10.2 ± 2.0	6.4 ± 5.7	2.0 ± 5.9	6.6 ± 4.5	6.7 ± 3.8	0.4 ± 6.6	9.8 ± 2.0
	7	3	3.6 (1.3–5.8)	2.6 ± 2.7	3.5 ± 3.3	5.6 ± 3.5	5.2 ± 6.1	2.6 ± 6.2	5.9 ± 5.6	9.6 ± 2.9	11.7 ± 3.6	11.9 ± 3.8
	8	88	8.7 (1.8–14.0)	24.9 ± 20.1	25.3 ± 19.9	31.3 ± 23.2	23.1 ± 19.5	23.8 ± 19.3	27.7 ± 20.6	19.6 ± 19.3	21.3 ± 19.3	28.0 ± 22.7
	9	36	7.0 (1.8–14.7)	2.9 ± 7.5	5.7 ± 6.5	15.1 ± 12.7	−0.1 ± 13.6	2.8 ± 12.3	9.3 ± 14.5	−1.5 ± 7.2	2.4 ± 6.3	12.2 ± 12.4
	10	16	4.6 (2.6–7.3)	3.4 ± 7.1	2.0 ± 10.0	5.7 ± 7.9	3.2 ± 6.1	2.4 ± 12.6	5.9 ± 11.0	19.9 ± 8.3	17.4 ± 11.5	21.7 ± 9.1
	Mean^†		6.1	14.0	13.2	19.9	10.8	10.6	15.5	17.6	16.2	24.1
¹⁸F-FPDTBZ	1	Kidney	11.7	24.3	28.8	28.5	6.9	8.3	9.9	26.6	28.6	32.0
		Pancreas	9.2	23.1	28.3	27.9	5.8	8.6	8.2	25.4	28.0	31.4
		Spine	1.4	−3.1	−19.7	−2.9	−2.0	−21.6	−1.9	−1.3	−19.9	−0.3
	2^‡	Kidney	14.7	31.2	25.7	34.4	20.3	23.0	21.9	—	—	—
		Pancreas	14.2	17.5	17.7	17.9	5.4	5.0	5.3	—	—	—
		Spine	2.8	−0.7	−35.6	−1.6	−3.8	−24.0	−5.5	—	—	—
¹⁸F-FMISO	1	Large tumor (avid area)	11.8	9.6	10.9	11.1	1.6	1.9	2.1	12.9	14.9	14.9
		Small tumor	5.3	15.0	21.1	21.6	8.6	17.1	17.3	18.4	25.5	25.8

↵* Mean and range of motion amplitudes estimated between end-inspiration and end-expiration gates across all lesions for each subject.
↵† 10 studies (323 ROIs).
↵‡ No SUR result is reported for study 2 since heart was out of field of view.